For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Small and emerging companies must make big decisions about what to do with their assets early in development. Should they seek venture capital (VC) funding to develop a product themselves or seek a partner once it shows clinical activity? They need to know their product candidate’s value and commercial viability to make the right decision, including the market size, growth and revenue potential.
Recent advances in machine learning and predictive analytics have empowered health economics and outcomes research (HEOR). Sophisticated tools are now available to help build a data-driven value story that can help attract investors and partners, convince payers, and benefit patients. Here are five ways biotech companies can enhance their value story with advanced analytics.
Are you using real-world evidence?
Feb 1, 2023
Addressing the Challenges of Artificial Intelligence used for Data Extraction in Systematic Literature Reviews
Mar 15, 2023
Use of AI to develop health economic evidence for optimized patient access
Sep 6, 2023
Three strategies for articulating a coherent product value story
Dec 18, 2021
Successful decentralized clinical trial (DCT) approaches
May 28, 2023
Pharma Talk Radio: Building a Successful Relationship with your Development Partner
Oct 5, 2021
Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data
Oct 15, 2021
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Clinical pharmacology, modeling and simulation to support FIH study design
Oct 21, 2021
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021